Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-PSMA-617 added to standard systemic therapy for poor responders with de novo metastatic hormone-sensitive prostate cancer
NL-OMON61118Phase 3Not yet recruiting
- Sponsor
- Unicancer
- Start
- Mar 2024
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of lutetium lu 177 vipivotide tetraxetan in prostate cancer (PCa), sponsored by Unicancer. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON61118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61118.